Argatroban

Drugs

Volumn 61, Issue 4, 2001, Pages 515-522

  McKeage, K ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DK 7419; HEPARIN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; VASCULAR SMOOTH MUSCLE;

EID: 0035056233     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161040-00005     Document Type: Review

References (36)

1. Antigens involved in heparin-induced thrombocytopenia
2. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management
3. The clinical management of heparin-induced thrombocytopenia
4. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis
5. Diagnostic and therapeutic strategies of white clot syndrome
6. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
7. Prolonged argatroban treatment does not result in the generation of neutralizing antibodies
8. Focus on argatroban
9. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor
10. Argatroban, a selective, potent thrombin inhibitor
11. A strategy for a rational approach to designing synthetic selective inhibitors
12. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
13. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin
14. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
15. -1 alcohol solution) in healthy man
16. Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures
17. Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: Implications in the monitoring and dosage optimizations in cardiovascular patients
18. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: Placebo controlled study
19. Argatroban and inhibition of the vasomotor actions of thrombin
20. Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells
21. Pharmacokinetic studies of argipidine (MD-805) -Protein binding and blood cell binding
22. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications
23. Pharmacokinetic studies of argipidine (MD-805) in human-concentrations of argipidine and its metabolites in plasma, urine and feces during and after drip intravenous infusion
24. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban
25. Lack of interaction between argatroban, a direct thrombin inhibitor, and 3 frequently prescribed medications, acetaminophen, lidocaine and digoxin
26. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
27. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
28. Argatroban use in patients with heparin-induced thrombocytopenia during percutaneous coronary intervention
29. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention (PCI) in patients with heparin-induced thrombocytopenia (HIT)
30. Results of phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT)
31. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and throm bosis syndrome: A case report
32. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia
33. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia
34. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis